Analysts’ Weekly Ratings Updates for Summit Therapeutics (SMMT)

Several analysts have recently updated their ratings and price targets for Summit Therapeutics (NASDAQ: SMMT):

• 10/1/2026 – Summit Therapeutics had its price target raised by Barclays PLC from $18.00 to $20.00. They now have an “equal weight” rating on the stock.
• 9/30/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 9/29/2026 – Summit Therapeutics was given a new $41.00 price target by The Goldman Sachs Group, Inc.. They now have a “buy” rating on the stock.
• 9/29/2026 – Summit Therapeutics was downgraded by Morgan Stanley to “outperform”.
• 9/29/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $30.00 price target on the stock.
• 9/25/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Citigroup Inc.. They now have a $43.00 price target on the stock, up from $40.00.
• 9/23/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by UBS Group AG.
• 9/23/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 9/22/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/9/2026 – Summit Therapeutics was given a new $25.00 price target by Summit Redstone.
• 9/8/2026 – Summit Therapeutics had its “buy” rating reaffirmed by UBS Group AG. They now have a $33.00 price target on the stock.
• 9/5/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/3/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 9/1/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 8/26/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Guggenheim.
• 8/26/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 8/25/2026 – Summit Therapeutics was given a new $11.90 price target by Summit Redstone.
• 8/25/2026 – Summit Therapeutics was upgraded by Sanford C. Bernstein from “underperform” to “market perform”. They now have a $11.90 price target on the stock, up from $9.80.
• 8/18/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 8/12/2026 – Summit Therapeutics was upgraded by Leerink Partners from “underperform” to “market perform”. They now have a $13.00 price target on the stock, up from $12.00.
• 8/6/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.

Summit Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company’s lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition targeting PD-1 with anti-angiogenic activity targeting VEGF. Summit is evaluating ivonescimab in clinical studies for multiple solid tumors, including non-small cell lung cancer.

Summit obtained exclusive rights from Akeso, Inc to develop and commercialize ivonescimab in markets outside China, including the United States and other international territories.